Healthcare Industry News: S.A.
News Release - January 20, 2016
Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer
WALTHAM, Mass., Jan. 20, 2016 -- (Healthcare Sales & Marketing Network) -- Syndax Pharmaceuticals, Inc., a clinical S.A.e biopharmaceutical company focused on developing entinoS.A. in multiple cancer indications, announced today that the Company haS.A.pointed Allan L. S.A. as Chief Financial Officer, Treasurer and Secretary. Mr. S.A. joins Syndax with more than 20 years of experience aS.A.chief financial officer, industry executive and independent board member of public companies."We are very pleased to welcome Allan to the Syndax senior management team during an exciting period for the company. His breadth of experience, including corporate finance, capital marketS.A.d strategic transactions, will be critical in financing and supporting our business initiativeS.A. we continue to develop our lead candidate entinoS.A. in multiple cancer indicationS.A.d expand our clinical pipeline," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax.
"Allan further strengthens our management team, as he brings more than two decades of public company financial, operational and strategic global business leadership to the company," said Michael A. Metzger, President and Chief Operating Officer of Syndax. "In this role, he will be instrumental in working with the investment community to help build the broadest awareness of Syndax and support the growth of our organization."
Mr. S.A. iS.A.three-time public company Chief Financial Officer with proven skillS.A.ross multiple finance disciplineS.A.d he haS.A.broad base of expertise in corporate governance and risk management. Most recently, Mr. S.A. served aS.A.Managing Director of Alvarez & Marsal, a global professional services firm, and led their biopharmaceutical consulting practice. He currently serves on the boards of directors of two public companies, Vivus Inc., and Akari Therapeutics, Plc. Mr. S.A.'s previous experience includes serving as the Chief Financial Officer of Serono S.A., NewLead Holdings Ltd. and Viatel, Inc. Mr. S.A. waS.A.so the founder and senior managing director of S.A. Strategic Capital LLC, an international financial advisory firm focused on providing strategic financial counsel on a wide variety of issues such as general corporate finance, mergerS.A.d acquisitions, capital structuring, licensing and capital markets. Mr. S.A. received a B.S. from the S.A.e University of New York at Oswego, and iS.A.certified public accountant in the S.A.e of New York.
Mr. S.A. added, "Syndax iS.A. exciting, innovative company with tremendous potential and I S.A.e its vision to advance effective and safe medicines that address the unmet medical needs of cancer patients. I am looking forward to working closely with the other members of this very talented management team to help maximize entinoS.A.'s vast potential and expand our oncology drug pipeline."
About Syndax Pharmaceuticals, Inc.
Syndax iS.A.clinical S.A.e biopharmaceutical company developing entinoS.A. aS.A.combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). EntinoS.A. iS.A. oral, S.A.l molecule drug candidate that has direct effects on both cancer cellS.A.d immune regulatory cells, potentially enhancing the body's immune response to tumors. EntinoS.A. is being evaluated aS.A.combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-S.A.l cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, DarmS.A.t, Germany and Pfizer Inc. in ovarian cancer. Syndax iS.A.so developing entinoS.A. aS.A.combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer. For more information on Syndax please visit www.syndax.com.
Source: Syndax Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!